<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="6">
  <stage>Registered</stage>
  <submitdate>8/07/2005</submitdate>
  <approvaldate>8/07/2005</approvaldate>
  <actrnumber>ACTRN12605000003673</actrnumber>
  <trial_identification>
    <studytitle>Bisphosphonate and Anastrozole trial - Bone Maintenance Algorithm Assessment</studytitle>
    <scientifictitle>Maintaining skeletal health in postmenopausal women with surgically resected Stage I-IIIa hormone-receptor positive breast cancer who are receiving anastrozole, through the use of alendronate as determined by the Osteoporosis Australia Bone Maintenance Algorithm</scientifictitle>
    <utrn />
    <trialacronym>BATMAN</trialacronym>
    <secondaryid>Andrew Love Cancer Centre: ALCC 04.02</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Breast Cancer</healthcondition>
    <conditioncode>
      <conditioncode1>Cancer</conditioncode1>
      <conditioncode2>Breast</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>This trial aims to assess the utility, through DEXA scans and biochemical markers of bone turnover, of a strategy of monitoring and intervention with oral alendronate in postmenopausal women with hormone-receptor positive breast cancer receiving five years of adjuvant anastrozole. It specifically addressed the issues of osteopaenic and osteoporotic women in this setting and will test three years versus five years of alendronate use.</interventions>
    <comparator>Five years of treatment with 70mg oral alendronate once weekly</comparator>
    <control>Active</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Changes in lumbar vertebra and femoral neck BMD T-score after 5 years of anastrozole treatment</outcome>
      <timepoint>After 5 years of anastrozole treatment</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percent change in the lumbar vertebrae</outcome>
      <timepoint>Annually for 5 years</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Biochemical markers</outcome>
      <timepoint>6 months after commencing alendronate</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Evaluate the Osteoporosis Australia strategy for bone protection for this patient group.</outcome>
      <timepoint>At 5 years</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Postmenopausal women- Adequately diagnosed and treated Stage I-IIIa early breast cancer- Oestrogen receptor and/or progesterone receptor positive breast cancer- Anastrozole is clinically indicated to be the best adjuvant strategy</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>Not stated</inclusivemaxagetype>
    <inclusivegender>Females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Clinical or radiological evidence of distant spread- prior treatment with bisphosphonates within the past 12 months</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Prevention</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>central randomisation via fax and phone</concealment>
    <sequence>Computer generated stratified blocks</sequence>
    <masking>Open (masking not used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>5/07/2005</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>300</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Closed: follow-up continuing</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Hospital</primarysponsortype>
    <primarysponsorname>Barwon Health</primarysponsorname>
    <primarysponsoraddress>272-322 Ryrie Street, Geelong, Victoria 3220</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Astra Zeneca</fundingname>
      <fundingaddress>P.O Box 131, North Ryde PBC NSW 1670</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname>Nil</sponsorname>
      <sponsoraddress>Nil</sponsoraddress>
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary />
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Barwon Health</ethicname>
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate />
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Associate Professor Richard Bell</name>
      <address>Andrew Love Cancer Centre
The Geelong Hospital
70 Swanston Street
Geelong VIC 3220</address>
      <phone>+61 3 52267855</phone>
      <fax>+61 3 52465168</fax>
      <email>richardb@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Ms Elaine Yeow</name>
      <address>Andrew Love Cancer Centre
The Geelong Hospital
70 Swanston Street
Geelong VIC 3220</address>
      <phone>+61 3 52267858</phone>
      <fax>+61 3 52465168</fax>
      <email>elainey@barwonhealth.org.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>